Johnson & Johnson stock (US4781601046): Q1 earnings beat and neuropsychiatry data

Johnson & Johnson reported Q1 2026 EPS of $2.70, beating estimates by $0.02, with revenue up 9.9% to $24.06B. Updated FY guidance and new neuropsychiatry portfolio news from May 11.

Johnson & Johnson announced Q1 2026 earnings on April 14, 2026, reporting adjusted EPS of $2.70, surpassing the consensus estimate of $2.68 by $0.02. Quarterly revenue increased 9.9% year-over-year to $24.06 billion, exceeding expectations of $23.60 billion, according to MarketBeat as of 05/08/2026. The company also raised its quarterly dividend to $1.34 per share.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Johnson & Johnson
• Sector/industry: Healthcare / Pharmaceuticals
• Headquarters/country: New Brunswick, New Jersey, USA
• Core markets: US, Europe, Asia
• Key revenue drivers: Innovative Medicine, MedTech
• Home exchange/listing venue: NYSE (JNJ)
• Trading currency: USD

Johnson & Johnson: core business model

Johnson & Johnson operates through two main segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals, including immunology, oncology, neuroscience, and infectious diseases. MedTech provides surgical equipment, orthopaedics, and vision care products. This diversified model serves global healthcare needs, with significant exposure to the US market as the largest revenue contributor, according to company reports.

The company's strategy emphasizes innovation and pipeline development, supporting long-term growth for US investors tracking healthcare leaders on NYSE.

Main revenue and product drivers for Johnson & Johnson

In Q1 2026, Innovative Medicine drove growth with strong sales in immunology and oncology. Revenue totaled $24.06 billion, up 9.9% YoY as reported on April 14, 2026, per MarketBeat as of 05/08/2026. Key products include blockbuster drugs in areas like rheumatoid arthritis and cancer treatments.

MedTech segment contributed through procedure-enabling technologies, benefiting from rising elective surgeries in the US. Annual revenue stood at $96.36 billion for the prior year, with net income of $26.80 billion published alongside Q1 results.

Industry trends and competitive position

The pharmaceuticals sector faces patent cliffs but benefits from biologics and neuro advancements. Johnson & Johnson holds a leading position with a robust pipeline, as highlighted in its May 11, 2026 press release on neuropsychiatry data at APA and ASCP meetings, via J&J as of 05/11/2026. Competitors include Pfizer and Merck.

Why Johnson & Johnson matters for US investors

Listed on NYSE, Johnson & Johnson offers US investors stability in healthcare, with 21.83% net margins and ROE of 32.60% per MarketBeat data as of May 2026. Its US headquarters and market dominance provide direct exposure to domestic healthcare spending trends.

Conclusion

Johnson & Johnson delivered a Q1 earnings beat with raised guidance and dividend, alongside fresh neuropsychiatry pipeline news. The stock traded at $221.17 on May 8, 2026 on NYSE, up 6.8% YTD per MarketBeat as of 05/08/2026. Investors monitor ongoing innovation amid sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.